Table 3.
Risk of bias assessment of eligible studies included in a meta-analysis of prolonged infusion versus intermittent infusion of β-lactams in hospitalized patients
| Study | Funding Source | Allocation Sequence Adequately Generated | Allocation Concealment | Masking | Similar Rates of Withdrawals Between Groups | Intention to Treat Analysis |
|---|---|---|---|---|---|---|
| Angus 2000 | Wellcome Trust of Great Britain | Unclear | Unclear | Unclear | Yes | No |
| Bodey 1979 | Pharmaceutical company | Yes | Yes | Unclear | Unclear | Yes |
| Buck 2005 | Pharmaceutical company | Unclear | Unclear | No | Yes | Yes |
| Georges 2005 | Not specified | Unclear | Unclear | No | Yes | Yes |
| Hanes 2000 | Pharmaceutical company | Unclear | Unclear | Unclear | Yes | No |
| Kojika 2005 | Not specified | Unclear | No | No | Yes | Yes |
| Lagast 1983 | Pharmaceutical company | Unclear | Unclear | Unclear | Yes | Yes |
| Lau 2006 | Pharmaceutical company | Unclear | Unclear | No | Yes | No |
| Lubasch 2003 | Pharmaceutical company | Unclear | Unclear | No | Unclear | Unclear |
| Merchant 2008 | Pharmaceutical company | Unclear | Unclear | No | Yes | Yes |
| Nicolau 2001 | Pharmaceutical company | Yes | Unclear | No | Yes | No |
| Rafati 2006 | Tehran University Medical Sciences Research Board | Unclear | Unclear | No | Yes | Yes |
| Roberts 2007 | National Health & Medical Research Council | Yes | Yes | Yesa | Yes | Yes |
| Van Zanten 2006 | Pharmaceutical company | Unclear | Unclear | No | No | No |
aOnly outcome assessors were masked